Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: Prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups

R. Bassan, E. Pogliani, P. Casula, G. Rossi, P. Fabris, S. Morandi, G. Lambertenghi-Deliliers, M. Vespignani, T. Lerede, A. Rambaldi, G. Borleri, P. Spedini, A. Cortelezzi, T. Izzi, P. Coser, G. Broccia, G. Corneo, T. Barbui

Research output: Contribution to journalArticle

Abstract

Introduction: Although definite risk classes are well known, risk-adapted modulation of first-line therapy is seldom attempted in adult ALL. So, a prospective validation of the therapeutic efficacy of a protocol (or a component thereof) in specific risk groups is uncommon. Materials and methods: From 1996-1999 a risk-oriented program (08/96) was evaluated in 102/121 unselected patients (median age 35 years, blast count 0-450 × 109/1, 100 Blin (lineage), 21 Tlin) responsive to induction therapy. The standard risk (SR) class was Blin CD10+ Ph- with blasts <10 × 109/1 (prior studies: disease-free survival (DFS) rate 52% at five years with dose-intensive anthracycline-containing programs). The SR protocol was therefore anthracycline-rich (early consolidation cycles with total idarubicin 96 mg/m2), and comprised long-term maintenance. High-risk (HR) patients were eligible to the following three options: allogeneic hematopoietic stem cell transplantation (HSCT) from related family donor; short sequence with high-dose cyclophosphamide-cytarabine-methotrexate followed by melphalan/total body irradiation with autologous HSCT; or Tlin ALL chemotherapy regimen inclusive of high-dose cytarabine and methotrexate. Results: Treatment realization and three-year DFS rates according to risk class, HR subset and postremission treatment intensity were the following. SR group (n = 28): realization rate 93%, DFS 68.5%. HR group (n = 74): realization rate 80%, DFS 39% (P = 0.052 vs SR category). In HR group, three-year DFS rates by disease subtype were the following. Blin Ph- (n=35) 43%; Ph+ (n = 19) 13% at 2.7 years (P=0.006 vs other HR subtypes); Tlin (n=18) 59.5%. And DFS rates by treatment intensity were: allograft (n = 21) 40%; autograft (n = 28) 27%; shift to SR protocol (n = 13) 52% (P = ns vs allograft/autograft); Tlin program (n = 10) 57%. Matched analyses of treatment protocols and disease subtypes suggested a possible therapeutic role of the autograft regimen in Blin Ph- ALL with a blast count 9/1, and of Tlin protocol for Tlin ALL. Comparisons with retrospective control cohorts were confirmatory of anthracycline activity in SR subclass. Conclusion: The intended strategy was applicable to the majority of study patients, confirming the value of anthracyclines in SR class and, preliminarily, the usefulness a Tlin- specific treatment. Apart from the case of Ph+ ALL, the indications for high-dose procedures with HSCT remains largely undetermined in this study.

Original languageEnglish
Pages (from-to)117-126
Number of pages10
JournalHematology Journal
Volume2
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Anthracyclines
Hematopoietic Stem Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transplants
Disease-Free Survival
Hematopoietic Stem Cell Transplantation
Autografts
Survival Rate
Cytarabine
Therapeutics
Methotrexate
Allografts
Idarubicin
Melphalan
Whole-Body Irradiation
Clinical Protocols

Keywords

  • ALL
  • Anthracyclines
  • DFS
  • High-dose treatments
  • Risk subsets

ASJC Scopus subject areas

  • Hematology

Cite this

Risk-oriented postremission strategies in adult acute lymphoblastic leukemia : Prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. / Bassan, R.; Pogliani, E.; Casula, P.; Rossi, G.; Fabris, P.; Morandi, S.; Lambertenghi-Deliliers, G.; Vespignani, M.; Lerede, T.; Rambaldi, A.; Borleri, G.; Spedini, P.; Cortelezzi, A.; Izzi, T.; Coser, P.; Broccia, G.; Corneo, G.; Barbui, T.

In: Hematology Journal, Vol. 2, No. 2, 2001, p. 117-126.

Research output: Contribution to journalArticle

Bassan, R, Pogliani, E, Casula, P, Rossi, G, Fabris, P, Morandi, S, Lambertenghi-Deliliers, G, Vespignani, M, Lerede, T, Rambaldi, A, Borleri, G, Spedini, P, Cortelezzi, A, Izzi, T, Coser, P, Broccia, G, Corneo, G & Barbui, T 2001, 'Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: Prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups', Hematology Journal, vol. 2, no. 2, pp. 117-126. https://doi.org/10.1038/sj.thj.6200091
Bassan, R. ; Pogliani, E. ; Casula, P. ; Rossi, G. ; Fabris, P. ; Morandi, S. ; Lambertenghi-Deliliers, G. ; Vespignani, M. ; Lerede, T. ; Rambaldi, A. ; Borleri, G. ; Spedini, P. ; Cortelezzi, A. ; Izzi, T. ; Coser, P. ; Broccia, G. ; Corneo, G. ; Barbui, T. / Risk-oriented postremission strategies in adult acute lymphoblastic leukemia : Prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. In: Hematology Journal. 2001 ; Vol. 2, No. 2. pp. 117-126.
@article{8826568a2dfc46c7aaa361c12c264778,
title = "Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: Prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups",
abstract = "Introduction: Although definite risk classes are well known, risk-adapted modulation of first-line therapy is seldom attempted in adult ALL. So, a prospective validation of the therapeutic efficacy of a protocol (or a component thereof) in specific risk groups is uncommon. Materials and methods: From 1996-1999 a risk-oriented program (08/96) was evaluated in 102/121 unselected patients (median age 35 years, blast count 0-450 × 109/1, 100 Blin (lineage), 21 Tlin) responsive to induction therapy. The standard risk (SR) class was Blin CD10+ Ph- with blasts <10 × 109/1 (prior studies: disease-free survival (DFS) rate 52{\%} at five years with dose-intensive anthracycline-containing programs). The SR protocol was therefore anthracycline-rich (early consolidation cycles with total idarubicin 96 mg/m2), and comprised long-term maintenance. High-risk (HR) patients were eligible to the following three options: allogeneic hematopoietic stem cell transplantation (HSCT) from related family donor; short sequence with high-dose cyclophosphamide-cytarabine-methotrexate followed by melphalan/total body irradiation with autologous HSCT; or Tlin ALL chemotherapy regimen inclusive of high-dose cytarabine and methotrexate. Results: Treatment realization and three-year DFS rates according to risk class, HR subset and postremission treatment intensity were the following. SR group (n = 28): realization rate 93{\%}, DFS 68.5{\%}. HR group (n = 74): realization rate 80{\%}, DFS 39{\%} (P = 0.052 vs SR category). In HR group, three-year DFS rates by disease subtype were the following. Blin Ph- (n=35) 43{\%}; Ph+ (n = 19) 13{\%} at 2.7 years (P=0.006 vs other HR subtypes); Tlin (n=18) 59.5{\%}. And DFS rates by treatment intensity were: allograft (n = 21) 40{\%}; autograft (n = 28) 27{\%}; shift to SR protocol (n = 13) 52{\%} (P = ns vs allograft/autograft); Tlin program (n = 10) 57{\%}. Matched analyses of treatment protocols and disease subtypes suggested a possible therapeutic role of the autograft regimen in Blin Ph- ALL with a blast count 9/1, and of Tlin protocol for Tlin ALL. Comparisons with retrospective control cohorts were confirmatory of anthracycline activity in SR subclass. Conclusion: The intended strategy was applicable to the majority of study patients, confirming the value of anthracyclines in SR class and, preliminarily, the usefulness a Tlin- specific treatment. Apart from the case of Ph+ ALL, the indications for high-dose procedures with HSCT remains largely undetermined in this study.",
keywords = "ALL, Anthracyclines, DFS, High-dose treatments, Risk subsets",
author = "R. Bassan and E. Pogliani and P. Casula and G. Rossi and P. Fabris and S. Morandi and G. Lambertenghi-Deliliers and M. Vespignani and T. Lerede and A. Rambaldi and G. Borleri and P. Spedini and A. Cortelezzi and T. Izzi and P. Coser and G. Broccia and G. Corneo and T. Barbui",
year = "2001",
doi = "10.1038/sj.thj.6200091",
language = "English",
volume = "2",
pages = "117--126",
journal = "Hematology Journal",
issn = "1466-4860",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Risk-oriented postremission strategies in adult acute lymphoblastic leukemia

T2 - Prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups

AU - Bassan, R.

AU - Pogliani, E.

AU - Casula, P.

AU - Rossi, G.

AU - Fabris, P.

AU - Morandi, S.

AU - Lambertenghi-Deliliers, G.

AU - Vespignani, M.

AU - Lerede, T.

AU - Rambaldi, A.

AU - Borleri, G.

AU - Spedini, P.

AU - Cortelezzi, A.

AU - Izzi, T.

AU - Coser, P.

AU - Broccia, G.

AU - Corneo, G.

AU - Barbui, T.

PY - 2001

Y1 - 2001

N2 - Introduction: Although definite risk classes are well known, risk-adapted modulation of first-line therapy is seldom attempted in adult ALL. So, a prospective validation of the therapeutic efficacy of a protocol (or a component thereof) in specific risk groups is uncommon. Materials and methods: From 1996-1999 a risk-oriented program (08/96) was evaluated in 102/121 unselected patients (median age 35 years, blast count 0-450 × 109/1, 100 Blin (lineage), 21 Tlin) responsive to induction therapy. The standard risk (SR) class was Blin CD10+ Ph- with blasts <10 × 109/1 (prior studies: disease-free survival (DFS) rate 52% at five years with dose-intensive anthracycline-containing programs). The SR protocol was therefore anthracycline-rich (early consolidation cycles with total idarubicin 96 mg/m2), and comprised long-term maintenance. High-risk (HR) patients were eligible to the following three options: allogeneic hematopoietic stem cell transplantation (HSCT) from related family donor; short sequence with high-dose cyclophosphamide-cytarabine-methotrexate followed by melphalan/total body irradiation with autologous HSCT; or Tlin ALL chemotherapy regimen inclusive of high-dose cytarabine and methotrexate. Results: Treatment realization and three-year DFS rates according to risk class, HR subset and postremission treatment intensity were the following. SR group (n = 28): realization rate 93%, DFS 68.5%. HR group (n = 74): realization rate 80%, DFS 39% (P = 0.052 vs SR category). In HR group, three-year DFS rates by disease subtype were the following. Blin Ph- (n=35) 43%; Ph+ (n = 19) 13% at 2.7 years (P=0.006 vs other HR subtypes); Tlin (n=18) 59.5%. And DFS rates by treatment intensity were: allograft (n = 21) 40%; autograft (n = 28) 27%; shift to SR protocol (n = 13) 52% (P = ns vs allograft/autograft); Tlin program (n = 10) 57%. Matched analyses of treatment protocols and disease subtypes suggested a possible therapeutic role of the autograft regimen in Blin Ph- ALL with a blast count 9/1, and of Tlin protocol for Tlin ALL. Comparisons with retrospective control cohorts were confirmatory of anthracycline activity in SR subclass. Conclusion: The intended strategy was applicable to the majority of study patients, confirming the value of anthracyclines in SR class and, preliminarily, the usefulness a Tlin- specific treatment. Apart from the case of Ph+ ALL, the indications for high-dose procedures with HSCT remains largely undetermined in this study.

AB - Introduction: Although definite risk classes are well known, risk-adapted modulation of first-line therapy is seldom attempted in adult ALL. So, a prospective validation of the therapeutic efficacy of a protocol (or a component thereof) in specific risk groups is uncommon. Materials and methods: From 1996-1999 a risk-oriented program (08/96) was evaluated in 102/121 unselected patients (median age 35 years, blast count 0-450 × 109/1, 100 Blin (lineage), 21 Tlin) responsive to induction therapy. The standard risk (SR) class was Blin CD10+ Ph- with blasts <10 × 109/1 (prior studies: disease-free survival (DFS) rate 52% at five years with dose-intensive anthracycline-containing programs). The SR protocol was therefore anthracycline-rich (early consolidation cycles with total idarubicin 96 mg/m2), and comprised long-term maintenance. High-risk (HR) patients were eligible to the following three options: allogeneic hematopoietic stem cell transplantation (HSCT) from related family donor; short sequence with high-dose cyclophosphamide-cytarabine-methotrexate followed by melphalan/total body irradiation with autologous HSCT; or Tlin ALL chemotherapy regimen inclusive of high-dose cytarabine and methotrexate. Results: Treatment realization and three-year DFS rates according to risk class, HR subset and postremission treatment intensity were the following. SR group (n = 28): realization rate 93%, DFS 68.5%. HR group (n = 74): realization rate 80%, DFS 39% (P = 0.052 vs SR category). In HR group, three-year DFS rates by disease subtype were the following. Blin Ph- (n=35) 43%; Ph+ (n = 19) 13% at 2.7 years (P=0.006 vs other HR subtypes); Tlin (n=18) 59.5%. And DFS rates by treatment intensity were: allograft (n = 21) 40%; autograft (n = 28) 27%; shift to SR protocol (n = 13) 52% (P = ns vs allograft/autograft); Tlin program (n = 10) 57%. Matched analyses of treatment protocols and disease subtypes suggested a possible therapeutic role of the autograft regimen in Blin Ph- ALL with a blast count 9/1, and of Tlin protocol for Tlin ALL. Comparisons with retrospective control cohorts were confirmatory of anthracycline activity in SR subclass. Conclusion: The intended strategy was applicable to the majority of study patients, confirming the value of anthracyclines in SR class and, preliminarily, the usefulness a Tlin- specific treatment. Apart from the case of Ph+ ALL, the indications for high-dose procedures with HSCT remains largely undetermined in this study.

KW - ALL

KW - Anthracyclines

KW - DFS

KW - High-dose treatments

KW - Risk subsets

UR - http://www.scopus.com/inward/record.url?scp=0035022777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035022777&partnerID=8YFLogxK

U2 - 10.1038/sj.thj.6200091

DO - 10.1038/sj.thj.6200091

M3 - Article

C2 - 11424004

AN - SCOPUS:0035022777

VL - 2

SP - 117

EP - 126

JO - Hematology Journal

JF - Hematology Journal

SN - 1466-4860

IS - 2

ER -